Core Insights - The biopharmaceutical industry is at a pivotal moment as it transitions from innovation-driven to value-driven paradigms, with a focus on sustainable growth paths amid global and local dynamics [1][5] Company Overview - As of the end of 2025, the company has established a comprehensive global operational system covering research, production, and commercialization, with products approved in over 60 markets, benefiting more than 95,000 patients globally [5][6] - The company has approximately 4,000 employees and has formed deep collaborative relationships with over 20 global partners, successfully launching 10 products worldwide [5][6] Product Development - The company has achieved a significant transformation from single product licensing to systematic value output, with 4 new products entering overseas markets, including the self-developed H drug Hanshuo® [6][7] - H drug Hanshuo® has become the only approved PD-1 inhibitor for small cell lung cancer in India, demonstrating the company's capability in gaining global regulatory recognition [6][7] Strategic Focus - The company aims to enhance scientific insight in defining therapeutic areas, moving from "fast-follow" to "differentiated innovation," focusing on unmet clinical needs [8][9] - It plans to deepen global collaborative innovation by building a resilient research network that attracts top global talent and fosters symbiotic relationships with local medical ecosystems [8][9] Localization Strategy - The company emphasizes the importance of local operational capabilities, transitioning from "going out" to "integrating in," by establishing production bases and commercialization teams to embed itself in the global industry chain [9] - The next three to five years are seen as a critical period for Chinese biopharmaceutical companies to build global competitiveness, with a focus on scientific foresight and operational resilience [9]
复宏汉霖朱俊：以系统化出海，构建全球竞争力新格局｜生物医药大健康2026思享汇